

Concise Synthesis of [1,1'-Biisoquinoline]-4,4'-diol *via* a Protecting Group Strategy and Its Application for Potential Liquid-Crystalline Compounds

by Elisabeth Kapatsina, Markus Mateescu, Angelika Baro, Wolfgang Frey, and Sabine Laschat*

Institut für Organische Chemie der Universität Stuttgart, Pfaffenwaldring 55, D-70569 Stuttgart
(phone: +49-711-68564565; fax: +49-711-68564285; e-mail: sabine.laschat@oc.uni-stuttgart.de)


Dedicated to Prof. *Helmut Schwarz* on the occasion of his 65th birthday

The [1,1'-biisoquinoline]-4,4'-diol (**4a**), which was obtained as hydrochloride **4a**·2 HCl in two steps starting from the methoxymethyl (MOM)-protected 1-chloroisoquinoline **8** (*Scheme 3*), opens access to further O-functionalized biisoquinoline derivatives. Compound **4a**·2 HCl was esterified with 4-(hexadecyloxy)benzoyl chloride (**5b**) to give the corresponding diester **3b** (*Scheme 4*), which could not be obtained by Ni-mediated homocoupling of **6b** (*Scheme 2*). The ether derivative **2b** was accessible in good yield by reaction of **4a**·2 HCl with the respective alkyl bromide **9** under the conditions of *Williamson* etherification (*Scheme 4*). Slightly modified conditions were applied to the esterification of **4a**·2 HCl with galloyl chlorides **10a–h** as well as etherification of **4a**·2 HCl with 6-bromohexyl tris(alkyloxy)benzoates **11b,d–h** and [(6-bromohexyl)oxy]-substituted pentakis(alkyloxy)triphenylenes **14a–c** (*Scheme 5*). Despite the bulky substituents, the respective target 1,1'-biisoquinolines **12**, **13**, and **15** were isolated in 14–86% yield (*Table*).


Introduction. – Biisoquinolines are highly attractive ligands for metal complexes because of their strong structural resemblance with bipyridines [1] and BINOL-derived ligands [2] (BINOL = [1,1'-binaphthalene]-2,2'-diol). However, in contrast to the latter, the chemistry of biisoquinolines has been explored to a much lesser extent. For example, *Kotora* and co-workers reported a sequence of *Sonogashira* coupling of α,ω -diynes with 1-chloroisoquinolines followed by a *Vollhardt* cyclization and oxidation with 3-chloroperbenzoic acid to give the corresponding bis-N-oxide, which was utilized in an asymmetric allylsilane addition to aldehydes [3]. *Knochel* and co-workers developed a *Negishi* coupling for 8,8'-biquinolines [4], while *Hashim* and *Kappe* published a microwave-assisted Ni-catalyzed homocoupling to [4,4'-biquinolin]-2-ones [5], and *Blakemore et al.* reported the enzymatic resolution of [8,8'-biquinoline]-7,7'-diols [6]. Very recently, we described the convenient synthesis of 4,4'-bifunctionalized 1,1'-biisoquinolines **2** from 1-chloroisoquinolin-4-ol (**1**) *via Williamson* etherification and Ni-mediated homocoupling (*Scheme 1*) [7].

The sequence **1** → **2** proceeded well for alkyl substituents even with long chain lengths, whereas (aryloxy)alkyl-substituted isoquinoline could still be coupled but with dramatically decreased yields [7]. The Ni-mediated homocoupling of the corresponding ester-functionalized isoquinoline to give **3**, however, failed completely (*Scheme 2*). Thus, in order to expand the scope of O-substituents in the 4,4'-positions of the 1,1'-

Scheme 1



Scheme 2



biisoquinoline, a more flexible approach is required. For this purpose, we envisioned [1,1'-biisoquinoline]-4,4'-diol (**4a**) as the key subunit (*Scheme 1*), which might be extended towards liquid-crystalline compounds (for reviews, see [8]). The results are discussed below.


Results and Discussion. – Initial attempts to obtain [1,1'-biisoquinoline]-4,4'-diol (**4a**) by deprotection of 4,4'-diethoxy-1,1'-biisoquinoline (**2a**, R = Et) with HBr/AcOH under reflux for 42 h according to the method of *Fukuda et al.* [9a] resulted in incomplete ether cleavage. Deprotection with BBr₃ and MeOH by using the procedure of *Finn* and co-workers [9b] provided a violet solid, from which the desired product **4a** could not be isolated. The direct homocoupling of 1-chloroisoquinolin-4-ol (**1**) with NiCl₂ · 6 H₂O, Ph₃P, and Zn in DMF at 70° following a procedure of *Bolm et al.* [10] did not yield any trace of **4a**. It should be noted that *Naumann* and *Langhals* obtained the homocoupling product from 3-bromoisoquinolin-4-ol under similar conditions in 27%

yield, whereas the 2-bromoquinolin-3-ol gave the homocoupling product only in trace amounts [11].

With regard to the analogous pyridine-3-ol, only O-protected derivatives were used for the Ni-mediated homocoupling [12]. Consequently, we prepared as potential homocoupling precursors both the ester derivatives **6a,b** and the allyl ether **7** from **1** by standard esterification [13] with acid chlorides **5a,b** in the presence of Et₃N in Et₂O and by treatment with allyl bromide and NaH in DMF, respectively (*Scheme 2*). However, neither the 1-chloroisoquinolin-4-yl carboxylates **6** nor the allyl protected isoquinoline **7** reacted under the usual Ni-mediated coupling conditions. Presumably, the ester and allylic moiety interfere with the Ni complex.

Therefore, we introduced the methoxymethyl (MOM) protecting group in **1**. Whereas treatment of **1** with dimethoxymethane in the presence of P₂O₅ in CH₂Cl₂ or acetone [14] at room temperature did not give any conversion due to the poor solubility of the starting material in both solvents, the methoxymethylation with MOMCl and K₂CO₃ in refluxing MeCN [13b] yielded product **8** in 47% (*Scheme 3*). The yield could be further improved to 81% analogously to [13b], where MOMCl was generated *in situ* from acetyl chloride, MeOH, and dimethoxymethane as described by *Amato et al.* [15]. Under the usual conditions, **8** was then coupled to give the 4,4'-MOM-protected biisoquinoline **4b** in 43% yield. Deprotection with conc. HCl in THF/*i*-PrOH at room temperature [16] provided the dihydrochloride **4a** · 2 HCl in 95% yield as a crystalline solid¹⁾ [17].


Scheme 3



In preliminary attempts, we demonstrated that [1,1'-biisoquinoline]-4,4'-diol (**4a** · 2 HCl) indeed may act as a precursor for further *O*-functionalization (*Scheme 4*). *O*-Acylation of **4a** · 2 HCl with 4-(hexadecyloxy)benzoyl chloride (**5b**) in the presence of Et₃N gave the target biisoquinoline diester **3b** in 16% yield. Also ether derivative **2b**, which was isolated under the homocoupling conditions only in very poor yields of 4% [7], was accessible in 50% yield from **4a** · 2 HCl by *Williamson* etherification with the respective bromide **9** and NaH in DMF at room temperature.

¹⁾ CCDC-701631 and 701632 contain the crystallographic data (excluding structural factors) of **4a** and those of 4,4'-diethoxy-1,1'-biisoquinoline (**2a**) [7]. These data can be obtained free of charge *via* [17].

Scheme 4




Based on these results, we extended the method to the derivatization of **4a**·2 HCl with mesogenic gallic acid (= 3,4,5-trihydroxybenzoic acid) derivatives **10** and **11** as well as (alkyloxy)triphenylenes **14** with regard to liquid-crystalline compounds (Scheme 5; Table). O-Acylation of **4a**·2 HCl with galloyl chlorides **10a–h** (which were easily obtained from the respective acids by chlorination with SOCl_2 [18]) in the presence of Et_3N afforded the 1,1'-biisoquinolinediyl diesters **12a–h** in 48–86% yield. The alkylation reagents **11b,d–h** were prepared by esterification of the galloyl chlorides **10b,d–h** with 6-bromohexan-1-ol in analogy to [19]. Bromides **11** and **4a**·2 HCl were linked *via* the hexyloxy chains in the presence of K_2CO_3 in DMF at 100° to give biisoquinolines **13b,d–h** in yields between 18 and 77%. Under the same

Table. O-Functionalization of **4a**·2 HCl via Esterification and Etherification (for details, see Scheme 5)

Halide	R	R ¹	Product	Yield [%]	M.p. [°]
10a	$\text{Me}(\text{CH}_2)_5$		12a	63	94
10b	$\text{Me}(\text{CH}_2)_7$		12b	74	76
10c	$\text{Me}(\text{CH}_2)_8$		12c	69	79
10d	$\text{Me}(\text{CH}_2)_9$		12d	84	81
10e	$\text{Me}(\text{CH}_2)_{10}$		12e	86	85
10f	$\text{Me}(\text{CH}_2)_{11}$		12f	49	88
10g	$\text{Me}(\text{CH}_2)_{13}$		12g	51	82
10h	$\text{Me}(\text{CH}_2)_{15}$		12h	48	82
11b	$\text{Me}(\text{CH}_2)_7$		13b	77	34
11d	$\text{Me}(\text{CH}_2)_9$		13d	32	69
11e	$\text{Me}(\text{CH}_2)_{10}$		13e	18	32
11f	$\text{Me}(\text{CH}_2)_{11}$		13f	21	52
11g	$\text{Me}(\text{CH}_2)_{13}$		13g	60	58
11h	$\text{Me}(\text{CH}_2)_{15}$		13h	36	67
14a	$\text{Me}(\text{CH}_2)_7$	Me	15a	69	101
14b	$\text{Me}(\text{CH}_2)_7$	$\text{Me}(\text{CH}_2)_7$	15b	31	69
14c	$\text{Me}(\text{CH}_2)_{11}$	$\text{Me}(\text{CH}_2)_{11}$	15c	14	66

Scheme 5



conditions, *O*-alkylation of **4a**·2 HCl with 2-[(6-bromohexyl)oxy]-3,6,7,10,11-pentakis-(alkyloxy)triphenylenes **14a–c** gave a third series of biisoquinolines **15a–c** bearing pentakis(alkyloxy)triphenylene moieties in the substituents. Triphenylenes **14** were accessible by trimerization of bis(alkyloxy)benzenes [20] to give the respective pentakis(alkyloxy)triphenylen-2-ols, which were converted with 1,6-dibromohexane in analogy to a method of *Kumar et al.* [21].

Conclusion. – A synthetic route to [1,1'-biisoquinoline]-4,4'-diol (**4a**) via protection with *in situ* generated MOMCl solution followed by Ni-catalyzed homocoupling and acidic deprotection could be established. Diol **4a**, isolated as hydrochloride **4a**·2 HCl, was found to be a key building block for *O*-alkylations and *O*-acylations resulting in a series of 1,1'-biisoquinolines **2**, **3**, **12**, **13**, and **15** tethered to (alkyloxy)benzenes, gallic acids, and triphenylenes. These substituents were chosen with regard to potential mesogenic properties. The physical investigations are currently under way.

Generous financial support by the *Deutsche Forschungsgemeinschaft*, the *Ministerium für Wissenschaft, Forschung und Kunst des Landes Baden-Württemberg* ('Landesgraduierten' fellowship

for E. K.), and the *Fonds der Chemischen Industrie* is gratefully acknowledged. We would like to thank Robert Hoffmann for his experimental contribution.

Experimental Part

1. *General.* Commercial reagents were used without further purification unless otherwise indicated. All solvents were distilled prior to use. Reactions were performed in oven-dried glassware. Flash chromatography (FC): silica gel 60 (230–400 mesh; *Fluka*). M.p.: *Büchi SMP 20*; uncorrected. IR Spectra: *Bruker-Vector-22-FT-IR* spectrophotometer; ATR = attenuated total reflection; in cm^{-1} . ^1H - and ^{13}C -NMR Spectra: *Bruker-Avance-300* and *-500* instrument; at 300 (^1H) and 75 (^{13}C) and 500 (^1H) and 125 MHz (^{13}C), resp.; δ in ppm, J in Hz; signal assignments are based on DEPT and COSY experiments. MS and ESI-MS: *Finnigan MAT 95*, *Varian MAT 711*, and *Bruker Daltonics microOTOF-Q*; APCI = atmospheric pressure chemical ionization; in m/z (rel. %). GC/MS: *Thermo-Electron-Corporation-Trace-DSQ* apparatus with *Macherey-Nagel-Optima-5-MS* column (30 m $\times$ 0.25 mm).

2.1. *1-Chloroisoquinolin-4-yl Tetradecanoate (6a).* To a suspension of **1** (718 mg, 4 mmol) in anhyd. Et_2O (40 ml), Et_3N (0.62 ml, 4.46 mmol) was added dropwise followed by tetradecanoyl chloride (**5a**; 1.0 ml, 1.08 g, 4.4 mmol) at 0° . After stirring at r.t. for another 24 h, 1M aq. NaHCO_3 (28 ml) was added and the org. layer washed with H_2O (28 ml). The combined aq. layer was extracted with Et_2O (2 $\times$ 40 ml) and the extract dried (Na_2SO_4) and concentrated: **6a** (1.46 g, 94%). Colorless solid. M.p. 75° . FT-IR (ATR): 2916s, 2849s, 1772m, 1471m, 1309m, 1258m, 1227m, 1119m, 1087s, 1021m, 963m, 913m, 772s, 744m, 717m, 641m. ^1H -NMR (300 MHz, CDCl_3): 0.88 (t, $J = 6.7$, Me); 1.24–1.50 (m, 10 CH_2); 1.80–1.90 (m, CH_2); 2.75 (t, $J = 7.5$, COOCH_2); 7.70–7.87 (m, H–C(6), H–C(7), H–C(5) or H–C(8)); 8.17 (s, H–C(3)); 8.33–8.37 (m, H–C(5) or H–C(8)). ^{13}C -NMR (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.0, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 31.9 (CH_2); 34.2 (COOCH_2); 121.1, 126.8, 128.9, 131.5 (C(5), C(8), C(6), C(7)); 127.5, 131.8 (C(4a), C(8a)); 134.2 (C(3)); 142.3, 148.1 (C(1), C(4)); 171.6 (C=O). GC/EI-MS: 389 (1, M^+), 354 (3, $[M - \text{Cl}]^+$), 211 (24, $[\text{C}_{13}\text{H}_{27}\text{CO}]^+$), 179 (100, $[M + \text{H} - \text{C}_{13}\text{H}_{27}\text{CO}]^+$), 123 (10), 85 (20), 71 (36), 57 (34). Anal. calc. for $\text{C}_{25}\text{H}_{32}\text{ClNO}_2$ (389.21): C 70.84, H 8.27, Cl 9.09, N 3.59 found: C 71.02, H 8.41, Cl 8.98, N 3.29.

2.2. *1-Chloroisoquinolin-4-yl 4-(Hexadecyloxy)benzoate (6b).* As described for **6a**, from **1** (359 mg, 2 mmol), 4-(hexadecyloxy)benzoyl chloride (**5b**, 914 mg, 2.4 mmol), and Et_3N (0.33 ml, 2.40 mmol): 681 mg (65%) of **6b**. Colorless solid. M.p. 115° . FT-IR (ATR): 2916s, 2850s, 1725s, 1604s, 1508m, 1468m, 1316m, 1257s, 1166s, 1152m, 1093s, 1039m, 1019m, 1001m, 958m, 901m, 844m, 760s, 721m, 691m, 675m, 640m. ^1H -NMR (300 MHz, CDCl_3): 0.88 (t, $J = 6.7$, Me); 1.23–1.43 (m, 12 CH_2); 1.44–1.54 (m, CH_2); 1.80–1.89 (m, CH_2); 4.08 (t, $J = 6.6$, CH_2O); 7.00–7.05 (m, H–C(3'), H–C(5')); 7.71–7.81 (m, H–C(6), H–C(7)); 7.91–7.95 (m, H–C(5) or H–C(8)); 8.22–8.27 (m, H–C(2'), H–C(6')); 8.29 (s, H–C(3)); 8.36–8.39 (m, H–C(5) or H–C(8)). ^{13}C -NMR (75 MHz, CDCl_3): 14.1 (Me); 22.7, 26.0, 29.1, 29.4, 29.57, 29.61, 29.67, 29.71, 31.9 (CH_2); 68.5 (CH_2O); 114.6 (C(3'), C(5')); 120.3, 127.6, 132.1 (C(1'), C(4a), C(8a)); 121.3, 126.7 (C(5), C(8)); 128.9, 131.5 (C(6), C(7)); 132.6 (C(2'), C(6')); 134.5 (C(3)); 142.7, 148.2 (C(1), C(4)); 164.1, 164.3 (C=O, C(4')). EI-MS (pos.): 523.3 (7, M^+), 488.3 (1, $[M - \text{Cl}]^+$), 345.3 (100, $[\text{C}_{16}\text{H}_{33}\text{OC}_6\text{H}_4\text{CO}]^+$), 121.1 (35, $[\text{OHC}_6\text{H}_4\text{CO}]^+$), 43.3 (10). Anal. calc. for $\text{C}_{32}\text{H}_{42}\text{ClNO}_3$ (523.28): C 73.33, H 8.08, Cl 6.76, N 2.67; found: C 73.42, H 8.04, Cl 6.77, N 2.58.

2.3. *[1,1'-Biisoquinoline]-4,4'-diyl Bis(4-(Hexadecyloxy)benzoate (3b)).* As described for **6a**, from **4a** $\cdot$ 2 HCl (29 mg, 0.08 mmol), **5b** (63 mg, 0.17 mmol), and Et_3N (0.06 ml, 0.44 mmol). Purification by dissolving in warm CH_2Cl_2 and precipitation with EtOH, yielded 13 mg (16%) of **3b**. Colorless solid. M.p. 110° . FT-IR (ATR): 1579m, 1561m, 1504m, 1447m, 1392m, 1311m, 1282m, 1158m, 1111m, 1079m, 1022m, 984m, 912s, 874m, 858m, 800m, 760s, 739s, 666m, 609s, 565m. ^1H -NMR (300 MHz, CDCl_3): 0.86–0.90 (m, 2 Me); 1.24–1.41 (m, 24 CH_2); 1.46–1.53, 1.82–1.91 (2m, 2 CH_2); 4.10 (t, $J = 6.5$, 2 CH_2O); 7.50–7.08, 8.31–8.34 (2m, 8 H, H–C(2'), H–C(3'), H–C(5'), H–C(6')); 7.53–7.59, 7.72–7.77 (2m, 4 H, H–C(6), H–C(7)); 7.93–7.96, 8.03–8.06 (2m, 4 H, H–C(5), H–C(8)); 8.71 (s, 2 H, H–C(3)). ^{13}C -NMR (125 MHz, CDCl_3): 14.1 (Me); 22.7, 26.0, 29.1, 29.38, 29.39, 29.58, 29.62, 29.67, 29.71, 31.9 (CH_2); 68.5 (CH_2O); 114.6, 132.7 (C(2'), C(3'), C(5'), C(6')); 120.6, 128.9, 131.2 (C(4a), C(8a), C(1')); 120.8, 127.6 (C(5), C(8)); 128.1, 130.8 (C(6), C(7)); 134.8 (C(3)); 143.0, 155.2, 164.0, 164.6 (C(1),

C(4), C(4'), C=O). ESI-MS: 977.64 ($[M+H]^+$), 858.42, 666.38, 617.38, 345.28. HR-ESI-MS (pos.): 977.6403 ($[M+H]^+$, $C_{64}H_{84}N_2O_6^+$; calc. 977.6402).

2.4. *[1,1'-Biisoquinoline]-4,4'-diyl Bis[3,4,5-tris(alkyloxy)benzoates 12a,c–f*. The bis-benzoates **12a,c–f** were prepared as described below for **12b,g,h**. For yields and m.p.s. of **12a–h**, see Table.

2.5. *[1,1'-Biisoquinolin]-4,4'-diyl Bis[3,4,5-tris(octyloxy)benzoate] (12b)*. As described for **6a**, from **4a**·2 HCl (50 mg, 0.138 mmol), **10b** (160 mg, 0.304 mmol), and Et_3N (1.0 ml, 726 mg, 7.21 mmol) in DMF (2 ml). Purification by FC (SiO_2 , hexanes/AcOEt 20:1 and 10:1; R_f 0.28) yielded 129 mg (74%) of **12b**. Light yellow waxy solid. FT-IR (ATR): 3065w, 2954m, 2920s, 2852s, 1736s, 1623w, 1584s, 1429s, 1335s, 1193s, 1115s, 1095s, 752s. 1H -NMR (300 MHz, $CDCl_3$): 0.87–0.93 (m, 6 Me); 1.26–1.43 (m, 24 CH_2); 1.48–1.58 (m, 6 CH_2); 1.76–1.92 (m, 6 CH_2); 4.12 (t, $J=6.5$, 8 H, $CH_2O-C(3'')$, $CH_2O-C(5'')$); 4.13 (t, $J=6.5$, 4 H, $CH_2O-C(4'')$); 7.58 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(7)); 7.59 (s, 4 H, H-C(2''), H-C(6'')); 7.76 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(6)); 7.95 (ddd, $J=8.5$, 1.2, 0.8, 2 H-C(8)); 8.03 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H-C(5)); 8.69 (s, 2 H, H-C(3)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.69, 22.72, 26.08, 26.12, 29.31, 29.33, 29.37, 29.40, 29.5, 30.4, 31.8, 31.9 (CH_2); 69.4 (CH_2O); 73.7 (CH_2O); 108.9 (C(2''), C(6'')); 120.9 (C(5)); 123.0 (C(1'')); 127.6 (C(8)); 128.1 (C(7)); 129.0 (C(8a)); 130.9 (C(6)); 131.1 (C(4a)); 134.9 (C(3)); 143.1 (C(4)); 143.6 (C(4'')); 153.2 (C(3''), C(5'')); 155.4 (C(1)); 164.8 (COO). APCI-MS: 1265.9 ($[M+H]^+$), 1145.9, 777.5 ($[M+2H-R]^+$), 693.4 ($[M+H-R-C_8H_{17}]^+$), 493.4. Anal. calc. for $C_{80}H_{116}N_2O_{10}$ (1265.78): C 75.91, H 9.24, N 2.21; found: C 75.82, H 9.12, N 2.21.

2.6. *[1,1'-Biisoquinoline]-4,4'-diyl Bis[3,4,5-tris(tetradecyloxy)benzoate] (12g)*. As described for **6a**, from **4a**·2 HCl (50 mg, 0.138 mmol), **10g** (236 mg, 0.304 mmol), and Et_3N (1.0 ml, 726 mg, 7.21 mmol) in DMF (2 ml). Purification by FC (SiO_2 , hexanes/AcOEt 20:1 and 10:1; R_f 0.47, yielded 125 mg (51%) of **12g**. FT-IR (ATR): 2920s, 2851s, 2185w, 1978w, 1732s, 1586s, 1430s, 1335s, 1194s, 1118s, 1056s, 758s. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.91 (m, 6 Me); 1.26–1.43 (m, 60 CH_2); 1.47–1.57 (m, 6 CH_2); 1.76–1.92 (m, 6 CH_2); 4.12 (t, $J=6.5$, 8 H, $CH_2O-C(3'')$, $CH_2O-C(5'')$); 4.12 (t, $J=6.5$, 4 H, $CH_2O-C(4'')$); 7.57 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(7)); 7.59 (s, 4 H, H-C(2''), H-C(6'')); 7.76 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(6)); 7.95 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H-C(8)); 8.03 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H-C(5)); 8.69 (s, 2 H, H-C(3)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1, 14.2 (Me); 21.1, 22.7, 26.11, 26.13, 29.3, 29.38, 29.41, 29.43, 29.6, 29.67, 29.68, 29.73, 29.8, 30.4, 31.9 (CH_2); 69.4 (CH_2O); 73.7 (CH_2O); 108.9 (C(2''), C(6'')); 120.9 (C(5)); 122.9 (C(1'')); 127.6 (C(8)); 128.2 (C(7)); 129.0 (C(8a)); 130.9 (C(6)); 131.2 (C(4a)); 134.8 (C(3)); 143.1 (C(4)); 143.6 (C(4'')); 153.2 (C(3''), C(5'')); 155.3 (C(1)); 164.8 (COO). APCI-MS: 1895.4, 1771.4 ($[M+H]^+$), 1729.5, 1550.2, 1431.2, 1387.2, 886.7, 741.7, 545.5, 351.3. Anal. calc. for $C_{166}H_{188}N_2O_{10}$ (1770.74): C 78.68, H 10.70, N 1.58; found: C 78.57, H 10.53, N 1.48.

2.7. *[1,1'-Biisoquinoline]-4,4'-diyl Bis[3,4,5-tris(hexadecyloxy)benzoate] (12h)*. As described for **6a**, from **4a**·2 HCl (50 mg, 0.138 mmol), **10h** (262 mg, 0.304 mmol), and Et_3N (1.0 ml, 726 mg, 7.21 mmol) in DMF (2 ml). Purification by FC (SiO_2 , hexanes/AcOEt 20:1 and 10:1; R_f 0.51, yielded 126 mg (48%) of **12h**. Light yellow waxy solid. FT-IR (ATR): 2916s, 2849s, 1737s, 1587s, 1503s, 1467s, 1430s, 1385m, 1336s, 1199s, 1122s, 1096s, 751s, 720s. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.91 (m, 6 Me); 1.26–1.43 (m, 72 CH_2); 1.47–1.57 (m, 6 CH_2); 1.76–1.92 (m, 6 CH_2); 4.12 (t, $J=6.5$, 8 H, $CH_2O-C(3'')$, $CH_2O-C(5'')$); 4.12 (t, $J=6.5$, 4 H, $CH_2O-C(4'')$); 7.57 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(7)); 7.59 (s, 4 H, H-C(2''), H-C(6'')); 7.76 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H-C(6)); 7.95 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H-C(8)); 8.03 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H-C(5)); 8.69 (s, 2 H, H-C(3)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1, 14.2 (Me); 22.7, 26.10, 26.14, 29.3, 29.38, 29.44, 29.6, 29.7, 29.8, 30.4, 31.9 (CH_2); 69.4 (CH_2O); 73.7 (CH_2O); 108.9 (C(2''), C(6'')); 120.9 (C(5)); 122.9 (C(1'')); 127.6 (C(8)); 128.2 (C(7)); 128.9 (C(8a)); 131.0 (C(6)); 131.2 (C(4a)); 134.7 (C(3)); 143.1 (C(4)); 143.6 (C(4'')); 153.2 (C(3''), C(5'')); 155.1 (C(1)); 164.8 (COO). APCI-MS: 2063.6, 1939.6 ($[M+H]^+$), 970.8, 825.8, 601.5, 379.3. Anal. calc. for $C_{128}H_{212}N_2O_{10}$ (1939.06): C 79.28, H 11.02, N 1.44; found: C 79.08, H 10.80, N 1.42.

3.1. *1-Chloro-4-(prop-2-en-1-yloxy)isoquinoline (7)*. A soln. of **1** (718 mg, 4 mmol) in anh. DMF (2 ml) was slowly added dropwise to a suspension of NaH (192 mg, 4.8 mmol) in anh. DMF (4 ml) at 0°. After stirring of the green soln. at r.t. for 1 h, 3-bromoprop-1-ene (0.7 ml, 968 mg, 8 mmol) was added at 0° (green → reddish-brown). The mixture was stirred at r.t. for another 5 h. Then, H_2O (20 ml) and CH_2Cl_2 (60 ml) were added. The org. layer was dried (Na_2SO_4), the solvent evaporated, and the residue purified by FC (SiO_2 , hexanes/AcOEt 6:1, R_f 0.47): **7** (607 mg, 69%). Colorless solid. M.p. 94°. IR (ATR): 2916s, 2849m, 1735m, 1605m, 1579m, 1510m, 1469m, 1250s, 1168s, 1150m, 1127m, 1076s, 1038m,

914m, 844m, 757s, 719m, 689m, 660m. ¹H-NMR (300 MHz, CDCl₃): 4.76–4.78 (m, CH₂); 5.36–5.41, 5.49–5.57 (2m, CH=CH₂); 6.09–6.22 (m, CH=CH₂); 7.68–7.79 (m, H–C(6), H–C(7)); 7.81 (s, H–C(3)); 8.25–8.28 (m, H–C(5), H–C(8)). ¹³C-NMR (125 MHz, CDCl₃): 69.6 (CH₂); 118.3 (CH=CH₂); 121.9, 126.0 (C(5), C(8)); 122.4 (C(3)); 127.0, 130.4 (C(4a), C(8a)); 128.8, 130.3 (C(6), C(7)); 132.3 (CH=CH₂); 142.7, 149.4 (C(1), C(4)). EI-MS (pos.): 219.0 (44, M⁺), 184.1 (72, [M – Cl]⁺), 150.0 (100). Anal. calc. for C₁₂H₁₀ClNO (219.67): C 65.61, H 4.59, N 6.31, Cl 16.14; found: C 65.52, H 4.63, N 6.38, Cl 16.25.

3.2. 4,4'-Bis[6-[4-(octyloxy)phenoxy]hexyl]oxy]-1,1'-biisoquinoline (**2b**). As described for **7**, from **4a** · 2 HCl (36 mg, 0.1 mmol) in anh. DMF (2 ml), NaH (18 mg, 0.44 mmol), and 1-[6-(bromohexyl)oxy]-4-(octyloxy)benzene (**9**; 85 mg, 0.2 mmol) in anh. DMF (2 ml): 45 mg (50%) of **2b**. Spectroscopic data: in accordance with those in [7].

4. 1-Chloro-4-(methoxymethoxy)isoquinoline (**8**). Method A. K₂CO₃ (5.53 g, 40.0 mmol) was added to a suspension of **1** (1.79 g, 10.0 mmol) in anh. MeCN (50 ml), and the mixture was heated under reflux for 30 min. Then, MOMCl (1.2 ml, 1.21 g, 15.0 mmol) was added and the mixture heated under reflux for another 12 h and filtered without cooling. The residue was washed with CH₂Cl₂ (3 × 20 ml) and the combined filtrate concentrated. The residue was taken up in CH₂Cl₂ (60 ml), the soln. washed with 0.5N aq. NaOH (2 × 25 ml) and H₂O (2 × 25 ml) and dried (Na₂SO₄), the solvent evaporated, and the residue purified by FC (SiO₂, hexanes/AcOEt 5 : 1, R_f 0.43); **8** (1.06 g, 47%). Yellowish solid.

Method B. A soln. of **1** (179 mg, 1 mmol) in anh. DMF (2 ml) was slowly added dropwise to a suspension of NaH (44 mg, 1.1 mmol) in anh. DMF (1.5 ml) at 0°, and the green mixture was stirred at r.t. for 1 h. Then, a 6N soln. of MOMCl [14] (0.2 ml, 1 mmol) was added at 0° (green → yellow). The mixture was stirred at r.t. for another 3 h, and then H₂O (10 ml) and CH₂Cl₂ (20 ml) were added. The org. layer was dried (Na₂SO₄) and the solvent evaporated: **8** (182 mg, 81%). Yellowish solid. M.p. 66°. FT-IR (ATR): 1312m, 1285m, 1211m, 1174m, 1151m, 1082m, 936s, 876s, 760s, 741m. ¹H-NMR (500 MHz, CDCl₃): 3.56 (s, Me); 5.40 (s, CH₂); 7.68 (ddd, J = 8.3, 6.9, 1.3, H–C(6) or H–C(7)); 7.75 (ddd, J = 8.3, 6.9, 1.3, H–C(6) or H–C(7)); 8.07 (s, H–C(3)); 8.21 (ddd, J = 8.3, 1.3, 0.8, H–C(5) or H–C(8)); 8.24 (ddd, J = 8.3, 1.3, 0.8, H–C(5) or H–C(8)). ¹³C-NMR (63 MHz, CDCl₃): 56.5 (Me); 95.3 (CH₂); 121.7 (C(3)); 125.1, 126.2 (C(5), C(8)); 127.1, 130.7 (C(4a), C(8a)); 128.7, 130.5 (C(6), C(7)); 143.6, 148.3 (C(1), C(4)). EI-MS: 223 (28, M⁺), 193 (4, [C₁₀H₁₁ClNO]⁺), 150 (10), 45 (100, [MeOCH₃]⁺). HR-ESI-MS (pos.): 246.0299 ([M + Na]⁺, C₁₁H₁₀ClNaO₂⁺; calc. 246.0298). Anal. calc. for C₁₁H₁₀ClNO₂ (223.66): C 59.07, H 4.51, Cl 15.85, N 6.26; found: C 59.16, H 4.54, Cl 15.76, N 6.01.

5. 4,4'-Bis(methoxymethoxy)-1,1'-biisoquinoline (**4b**). A soln. of NiCl₂ · 6 H₂O (808 mg, 3.40 mmol) in degassed anh. DMF (15 ml) was heated at 70° (bath temp.), and Ph₃P (3.56 g, 13.7 mmol) and Zn (237 mg, 3.65 mmol) were added. The mixture became brown and was heated at 70° for 1 h. Then, a soln. of **8** (525 mg, 2.79 mmol) in degassed anh. DMF (5 ml) was added and the mixture stirred at 70° for 4 h (TLC control). After cooling to r.t., the mixture was quenched with 5% NH₃ soln. (21 ml). The aq. layer extracted with CH₂Cl₂/Et₂O 2 : 1 (3 × 25 ml), the combined org. phase concentrated, and the residue taken up in CH₂Cl₂ (15 ml), washed with H₂O (4 × 8 ml) and brine (1 × 10 ml), dried (Na₂SO₄), and concentrated. The crude product was purified by FC (SiO₂, hexanes/AcOEt 1 : 2; R_f (AcOEt) = 0.54): **4b** (220 mg, 43%). M.p. 135°. FT-IR (ATR): 1579m, 1292m, 1279m, 1150s, 1085m, 1063s, 1018m, 960s, 928m, 902m, 861m, 773m, 687m. ¹H-NMR (300 MHz, CDCl₃): 3.62 (s, Me); 5.51 (s, CH₂); 7.49 (ddd, J = 8.4, 7.0, 1.3, H–C(6) or H–C(7)); 7.71 (ddd, J = 8.4, 7.0, 1.3, H–C(6) or H–C(7)); 7.79 (ddd, J = 8.4, 1.3, 0.7, H–C(5) or H–C(8)); 8.33 (ddd, J = 8.4, 1.3, 0.7, H–C(5) or H–C(8)); 8.48 (s, H–C(3)). ¹³C-NMR (75 MHz, CDCl₃): 56.5 (Me); 95.2 (CH₂); 121.2, 127.0 (C(5), C(8)); 125.7 (C(3)); 127.6, 129.6 (C(6), C(7)); 128.6, 129.3 (C(4a), C(8a)); 148.2, 151.7 (C(1), C(4)). GC/EI-MS: 376 (100, M⁺), 345 (12), 331 (94, [M – CH₂OMe]⁺), 315 (10), 301 (40, [M + H – CH₂OMe – OMe]⁺), 287 (38, [M + H – 2CH₂OMe]⁺), 270 (48), 258 (24), 242 (12), 229 (22), 214 (20), 207 (46), 191 (18), 176 (26), 150 (8), 130 (10), 115 (8), 78 (20, Ph⁺). HR-ESI-MS (pos.): 377.1499 ([M + H]⁺, C₂₂H₂₀N₂O₄⁺; calc. 377.1496).

6. [1,1'-Biisoquinoline]-4,4'-diol Hydrochloride (1:2) (**4a** · 2 HCl). Conc. HCl soln. (0.2 ml) was added to a soln. of **4b** (36 mg, 0.096 mmol) in THF/i-PrOH 1 : 1 (10 ml), and the mixture was stirred at r.t. for 7 h. The solvent was evaporated: **4a** · 2 HCl (33 mg, 95%). Yellow solid. M.p. > 240°. FT-IR (ATR): 2860m, 2324m, 1984m, 1581s, 1495m, 1454m, 1389s, 1358s, 1265m, 1084m, 842m, 771s, 716m, 584m. ¹H-NMR (300 MHz, CD₃OD): 7.70–7.73 (m, 2 H, H–C(5) or H–C(8)); 7.81–7.86, 8.05–8.10 (2m, 4 H,

H–C(6), H–C(7)); 8.26 (*s*, 2 H, H–C(3)); 8.60–8.63 (*m*, 2 H, H–C(5) or H–C(8)). ^{13}C -NMR (125 MHz, $(\text{D}_6)\text{DMSO}$): 121.2 (C(3)); 122.1, 127.0 (C(5), C(8)); 130.2, 132.2 (C(6), C(7)); 128.1, 129.0 (C(4a), C(8a)); 141.5, 152.0 (C(1), C(4)). ESI-MS: 289.10 ($[M + \text{H}]^+$), 311.08 ($[M + \text{Na}]^+$). Anal. calc. for $\text{C}_{18}\text{H}_{14}\text{Cl}_2\text{N}_2\text{O}_2$ (361.23): C 59.85, H 3.91, Cl 19.63, N 7.76; found: C 59.71, H 4.05, Cl 19.39, N 7.63.

7.1. 6-Bromohexyl 3,4,5-Tris(alkyloxy)benzoates **11d–f**. The benzoates **11d–f** were prepared as described below for **11b,g,h**.

7.2. 6-Bromohexyl 3,4,5-Tris(octyloxy)benzoate (**11b**). In analogy to [19], **10b** (877 mg, 1.67 mmol) was added to a soln. of 6-bromohexan-1-ol (0.18 ml, 0.25 g, 1.41 mmol) and Et_3N (0.5 ml, 0.37 g, 3.61 mmol) in CH_2Cl_2 (10 ml), and the mixture was stirred at r.t. for 2 h. The solvent was evaporated and the residue purified by FC (SiO_2 , hexanes/AcOEt 40 : 1; R_f 0.48): **11b** (651 mg, 64%). M.p. 10°. FT-IR (ATR): 2923s, 2855s, 2366w, 2168w, 2003w, 1715s, 1586s, 1499m, 1465m, 1428s, 1381m, 1332s, 1212s, 1110s, 1043m, 1008m, 853m, 764s, 723m. ^1H -NMR (300 MHz, CDCl_3): 0.86–0.91 (*m*, 3 Me); 1.24–1.40 (*m*, 12 CH_2); 1.43–1.54 (*m*, 10 H, CH_2 , 2 H–C(3'), 2 H–C(4')); 1.70–1.94 (*m*, 10 H, CH_2 , 2 H–C(2'), 2 H–C(5')); 3.42 (*t*, $J = 6.8$, 2 H–C(6')); 4.01 (2*t*, $J = 6.5$, CH_2O –C(3''), CH_2O –C(4''), CH_2O –C(5'')); 4.30 (*t*, $J = 6.7$, 2 H–C(1'')); 7.24 (*s*, H–C(2''), H–C(6'')). ^{13}C -NMR (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.2, 26.06, 26.11, 26.9, 27.8, 28.6, 29.30, 29.33, 29.4, 29.5, 30.3, 31.8, 31.9, 32.6 (CH_2 , C(2'), C(3'), C(4'), C(5')); 33.6 (C(6')); 64.8 (C(1'')); 69.2 (CH_2O); 73.5 (CH_2O); 108.0 (C(2''), C(6'')); 124.9 (C(1'')); 142.4 (C(4'')); 152.8 (C(3''), C(5'')); 166.5 (COO). ESI-MS: 669.4 ($[M + \text{H}]^+$), 507.4 ($[M + \text{H} - \text{BrC}_6\text{H}_{13}]^+$), 395.3 ($[M + 2 \text{H} - \text{BrC}_6\text{H}_{13} - \text{C}_8\text{H}_{17}]^+$). HR-ESI-MS: 669.4080 and 671.4067 ($[M + \text{H}]^+$, $\text{C}_{37}\text{H}_{65}\text{BrO}_3^+$; calc. 669.4088 and 671.4075).

7.3. 6-Bromohexyl 3,4,5-Tris(tetradecyloxy)benzoate (**11g**). As described for **11b**, from **10g** (1.04 g, 1.34 mmol), 6-bromohexan-1-ol (0.18 ml, 0.25 g, 1.41 mmol), and Et_3N (0.5 ml, 0.37 g, 3.61 mmol): 497 mg (37%) of **11g**. R_f 0.61 (hexanes/AcOEt 20 : 1). M.p. 41°. FT-IR (ATR): 2915s, 2849s, 2362w, 1703s, 1585m, 1466m, 1429s, 1346s, 1334s, 1255s, 1219s, 1121s, 994s, 767s, 725m, 651m. ^1H -NMR (300 MHz, CDCl_3): 0.86–0.90 (*m*, 3 Me); 1.26–1.38 (*m*, 30 CH_2); 1.43–1.54 (*m*, 10 H, CH_2 , 2 H–C(3'), 2 H–C(4')); 1.69–1.94 (*m*, 10 H, CH_2 , 2 H–C(2'), 2 H–C(5')); 3.42 (*t*, $J = 6.8$, 2 H–C(6')); 4.01 (2*t*, $J = 6.5$, CH_2O –C(3''), CH_2O –C(4''), CH_2O –C(5'')); 4.30 (*t*, $J = 6.7$, 2 H–C(1'')); 7.24 (*s*, H–C(2''), H–C(6'')). ^{13}C -NMR (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.3, 26.1, 27.8, 28.6, 29.36, 29.39, 29.43, 29.6, 29.66, 29.69, 29.73, 30.4, 32.0, 32.6 (CH_2 , C(2'), C(3'), C(4'), C(5'')); 33.6 (C(6'')); 64.8 (C(1'')); 69.2 (CH_2O); 73.5 (CH_2O); 108.1 (C(2''), C(6'')); 125.0 (C(1'')); 142.5 (C(4'')); 152.8 (C(3''), C(5'')); 166.5 (COO). (APCI)-MS: 923.7 ($[M + \text{H}]^+$), 773.7, 759.7 ($[M + \text{H} - \text{BrC}_6\text{H}_{13}]^+$), 727.5, 577.48, 563.5, 519.5, 367.3, 323.3. HR-APCI-MS: 921.6869 and 923.6867 ($[M + \text{H}]^+$, $\text{C}_{55}\text{H}_{101}\text{BrO}_3^+$; calc. 921.6905 and 923.6899).

7.4. 6-Bromohexyl 3,4,5-Tris(hexadecyloxy)benzoate (**11h**). As described for **11b**, from **10h** (3.00 g, 3.48 mmol), 6-bromohexan-1-ol (0.18 ml, 0.25 g, 1.41 mmol), and Et_3N (0.5 ml, 0.37 g, 3.61 mmol): 2.18 g (62%) of **11h**. R_f 0.52 (hexanes/AcOEt 20 : 1). M.p. 46°. FT-IR (ATR): 2916s, 2849s, 2169w, 1975w, 1707s, 1587m, 1502m, 1467s, 1429s, 1335s, 1219s, 1121s, 988m, 765m, 721s. ^1H -NMR (300 MHz, CDCl_3): 0.86–0.90 (*m*, 3 Me); 1.26–1.38 (*m*, 36 CH_2); 1.43–1.54 (*m*, 10 H, CH_2 , 2 H–C(3'), 2 H–C(4')); 1.69–1.94 (*m*, 10 H, CH_2 , 2 H–C(2'), 2 H–C(5'')); 3.42 (*t*, $J = 6.8$, 2 H–C(6'')); 4.01 (2*t*, $J = 6.5$, CH_2O –C(3''), CH_2O –C(4''), CH_2O –C(5'')); 4.30 (*t*, $J = 6.7$, 2 H–C(1'')); 7.24 (*s*, H–C(2''), H–C(6'')). ^{13}C -NMR (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.2, 26.08, 26.11, 27.8, 28.6, 29.3, 29.40, 29.43, 29.6, 29.67, 29.69, 29.74, 30.3, 32.0 (CH_2 , C(2'), C(3'), C(4'), C(5'')); 33.6 (C(6'')); 64.8 (C(1'')); 69.2 (CH_2O); 73.5 (CH_2O); 108.0 (C(2''), C(6'')); 124.9 (C(1'')); 142.4 (C(4'')); 152.8 (C(3''), C(5'')); 166.5 (COO). APCI-MS: 1007.8 ($[M + \text{H}]^+$), 961.8, 843.8 ($[M + \text{H} - \text{BrC}_6\text{H}_{13}]^+$), 825.8, 783.5, 619.5, 575.5, 395.3, 351.3. HR-MS (APCI): 1005.7830 and 1007.7835 ($[M + \text{H}]^+$, $\text{C}_{61}\text{H}_{113}\text{BrO}_3^+$; calc. 1005.7844 and 1007.7841).

8. 3-Methoxy-6,7,10,11-tetrakis(octyloxy)triphenylen-2-ol. In analogy to [20b], anh. FeCl_3 (13.4 g, 0.120 mol) was added portionwise to a soln. of 1,2-bis(octyloxy)benzene (10.0 g, 29.9 mmol) and guaiacol (=2-methoxyphenol; 7.42 g, 59.8 mmol) in anh. CH_2Cl_2 (80 ml) at 0°, while N_2 was passed through the soln. The mixture was stirred at r.t. for 2 h, then poured in cold MeOH (100 ml), and the CH_2Cl_2 was evaporated. The dark green precipitate was filtered off and separated by FC (SiO_2 , hexanes/AcOEt 40 : 1, 20 : 1, 10 : 1, and 5 : 1): 3,6,7,10,11-pentakis(octyloxy)triphenylen-2-ol (145 mg, 2%), 2,3,6,7,10,11-hexakis(octyloxy)triphenylene (3.66 g, 36%), and the title product (774 mg, 10%). R_f 0.35 (hexanes/AcOEt 10 : 1). M.p. 109°. FT-IR (ATR): 3535m, 2919s, 2850s, 2184w, 1974w, 1617m, 1514s, 1448s, 1427s, 1386m,

1259s, 1166s, 1043.7s, 835s, 792s. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 0.87–0.92 (*m*, 4 Me); 1.26–1.47 (*m*, 16 CH_2); 1.51–1.61 (*m*, 4 CH_2); 1.90–1.99 (*m*, 4 CH_2); 4.13 (*s*, MeO); 4.18–4.25 (*m*, $\text{CH}_2\text{O}-\text{C}(6'')$, $\text{CH}_2\text{O}-\text{C}(7'')$, $\text{CH}_2\text{O}-\text{C}(10'')$, $\text{CH}_2\text{O}-\text{C}(11'')$); 5.86 (*br. s*, OH); 7.78–7.96 (*m*, 6 arom. H). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 14.1 (Me); 22.7, 26.17, 26.23, 29.4, 29.47, 29.51, 29.6, 30.9, 31.9 (CH_2); 56.1 (MeO); 69.2, 69.7, 69.9 (CH_2O); 103.5, 106.6, 107.4, 107.5, 107.6 ($\text{C}(1'')$, $\text{C}(4'')$, $\text{C}(5'')$, $\text{C}(8'')$, $\text{C}(9'')$, $\text{C}(12'')$); 123.0, 123.3, 123.59, 123.61, 123.7, 124.1 ($\text{C}(4''\text{a})$, $\text{C}(4''\text{b})$, $\text{C}(8''\text{a})$, $\text{C}(8''\text{b})$, $\text{C}(12''\text{a})$, $\text{C}(12''\text{b})$); 145.1 ($\text{C}(2'')$); 146.4 ($\text{C}(3'')$); 148.8, 148.9, 149.1, 149.2 ($\text{C}(6'')$, $\text{C}(7'')$, $\text{C}(10'')$, $\text{C}(11'')$). APCI-MS: 787.58 ($[M+H]^+$), 675.5 ($[M+H-\text{C}_8\text{H}_{18}]^+$), 658.5, 563.3, 451.2, 433.2, 339.1. Anal. calc. for $\text{C}_{51}\text{H}_{78}\text{O}_6$ (787.16): C 77.82, H 9.99; found: C 77.63, H 9.84.

9.1. **3,6,7,10,11-Pentakis(octyloxy)triphenylen-2-ol**. In analogy to [20a], bis(octyloxy)benzene (10.0 g, 29.9 mmol) was added to a suspension of anhyd. FeCl_3 (14.5 g, 90.0 mmol) and conc. H_2SO_4 (3 drops) in anhyd. CH_2Cl_2 (80 ml) at 0° , while N_2 was passed through the soln. The mixture was stirred at r.t. for 1 h, then cold MeOH was added, and the CH_2Cl_2 was evaporated. The precipitate was filtered off and separated by FC (SiO_2 , hexanes/AcOEt 50:1, and 40:1): 2,3,6,7,10,11-hexakis(octyloxy)triphenylene (5.56 g, 56%) and the title product (1.36 g, 15%). The spectroscopic data were in accordance with those in [22].

9.2. **3,6,7,10,11-Pentakis(dodecyloxy)triphenylen-2-ol**. As described in 9.1, from bis(dodecyloxy)benzene (12.0 g, 26.8 mmol): 2.95 g (28%) of the title product. R_f 0.72 (hexanes/AcOEt 10:1). M.p. 84° . FT-IR (ATR): 3557w, 2917s, 2849s, 2368w, 2119w, 1975w, 1617m, 1515s, 1437s, 1259s, 1168s, 1044s, 835s, 721m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 0.86–0.90 (*m*, 5 Me); 1.21–1.46 (*m*, 40 CH_2); 1.51–1.61 (*m*, 5 CH_2); 1.88–1.98 (*m*, 5 CH_2); 4.18–4.24 (*m*, 5 CH_2O); 5.90 (*br. s*, OH); 7.76–7.96 (*m*, 6 arom. H). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 14.1 (Me); 22.7, 26.16, 26.20, 26.23, 29.37, 29.40, 29.5, 29.57, 29.64, 29.66, 29.70, 29.72, 29.8, 31.9 (CH_2); 69.1, 69.6, 69.7, 69.9 (CH_2O); 106.5, 107.2, 107.3, 107.4, 107.6 ($\text{C}(1'')$, $\text{C}(4'')$, $\text{C}(5'')$, $\text{C}(8'')$, $\text{C}(9'')$, $\text{C}(12'')$); 123.0, 123.2, 123.5, 123.59, 123.61, 123.7, 123.9 ($\text{C}(4''\text{a})$, $\text{C}(4''\text{b})$, $\text{C}(8''\text{a})$, $\text{C}(8''\text{b})$, $\text{C}(12''\text{a})$, $\text{C}(12''\text{b})$); 145.2, 145.8, 148.7, 148.9, 149.0, 149.1 ($\text{C}(2'')$, $\text{C}(3'')$, $\text{C}(6'')$, $\text{C}(7'')$, $\text{C}(10'')$, $\text{C}(11'')$). APCI-MS: 1166.0 ($[M+H]^+$), 997.8 ($[M+H-\text{C}_{12}\text{H}_{26}]^+$), 829.6, 661.4, 643.4, 493.3, 325.1. HR-APCI-MS: 1166.0088 ($[M+H]^+$, $\text{C}_{78}\text{H}_{132}\text{O}_6$; calc. 1166.0097).

10.1. **2-[(6-Bromohexyl)oxy]-3-methoxy-6,7,10,11-tetrakis(octyloxy)triphenylene (14a)**. In analogy to [21], a suspension of anhyd. K_2CO_3 (0.93 g, 6.70 mmol) and 3-methoxy-6,7,10,11-tetrakis(octyloxy)triphenylen-2-ol (739 mg, 934 μmol) in butan-2-one (60 ml) was stirred at 95° for 30 min. Then, 1,6-dibromohexane (2.12 g, 8.93 mmol) was added and the mixture stirred at 95° for another 16 h. The mixture was filtered and the residue washed with CH_2Cl_2 . The filtrate was concentrated and the residue purified by FC (SiO_2 , hexanes/AcOEt 40:1, 20:1, 10:1): **14a** (790 mg, 89%). R_f 0.48 (hexanes/AcOEt 10:1). M.p. 44° . FT-IR (ATR): 3098w, 2920s, 2850s, 2366w, 2179w, 1974w, 1617m, 1517s, 1428s, 1258s, 1165s, 1048s, 836s, 723m. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 0.87–0.92 (*m*, 4 Me); 1.28–1.47 (*m*, 16 CH_2); 1.53–1.62 (*m*, 12 H, CH_2 , 2 H– $\text{C}(3')$, 2 H– $\text{C}(4')$); 1.89–2.00 (*m*, 12 H, CH_2 , 2 H– $\text{C}(2')$, 2 H– $\text{C}(5')$); 3.44 (*t*, $J=6.8$, 2 H– $\text{C}(6')$); 4.10 (*s*, MeO); 4.23 (*m*, 5 CH_2O); 7.80–7.85 (*m*, 6 arom. H). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.4, 26.2, 28.0, 29.2, 29.4, 29.5, 31.9, 32.7 (CH_2 , $\text{C}(2')$, $\text{C}(3')$, $\text{C}(4')$, $\text{C}(5')$); 33.8 ($\text{C}(6')$); 56.3 (MeO); 69.1 ($\text{C}(1')$); 69.70, 69.74, 69.8 (CH_2O); 105.0, 106.4, 107.3, 107.4 ($\text{C}(1'')$, $\text{C}(4'')$, $\text{C}(5'')$, $\text{C}(8'')$, $\text{C}(9'')$, $\text{C}(12'')$); 123.4, 123.45, 123.52, 123.7 ($\text{C}(4''\text{a})$, $\text{C}(4''\text{b})$, $\text{C}(8''\text{a})$, $\text{C}(8''\text{b})$, $\text{C}(12''\text{a})$, $\text{C}(12''\text{b})$); 148.3, 149.0, 149.1, 149.2 ($\text{C}(2'')$, $\text{C}(3'')$, $\text{C}(6'')$, $\text{C}(7'')$, $\text{C}(10'')$, $\text{C}(11'')$). APCI-MS: 951.6 ($[M+H]^+$), 839.5 ($[M+H-\text{C}_8\text{H}_{18}]^+$), 787.6 ($[M+H-\text{BrC}_6\text{H}_{13}]^+$), 727.3, 675.5, 597.2, 563.3, 451.2, 339.1. HR-APCI-MS: 949.5911 and 951.5907 ($[M+H]^+$, $\text{C}_{57}\text{H}_{89}\text{BrO}_6$; calc. 949.5915 and 951.5910).

10.2. **2-[(6-Bromohexyl)oxy]-3,6,7,10,11-pentakis(octyloxy)triphenylene (14b)**. As described for **14a**, from 3,6,7,10,11-pentakis(octyloxy)triphenylen-2-ol (988 mg, 1.12 mmol) and 1,6-dibromohexane (2.12 g, 8.93 mmol): 1.01 g (86%) of **14b**. R_f 0.78 (hexanes/AcOEt 10:1). M.p. 53° . FT-IR (ATR): 2917s, 2849s, 1616m, 1517s, 1434s, 1258s, 1171s, 1029s, 855s, 603s. $^1\text{H-NMR}$ (300 MHz, CDCl_3): 0.88–0.92 (*m*, 5 Me); 1.26–1.47 (*m*, 20 CH_2); 1.53–1.66 (*m*, 14 H, CH_2 , 2 H– $\text{C}(3')$, 2 H– $\text{C}(4')$); 1.89–1.98 (*m*, 14 H, CH_2 , 2 H– $\text{C}(2')$, 2 H– $\text{C}(5')$); 3.44 (*t*, $J=6.8$, 2 H– $\text{C}(6')$); 4.20–4.25 (*m*, 6 CH_2O); 7.84 (*s*, 6 arom. H). $^{13}\text{C-NMR}$ (75 MHz, CDCl_3): 14.1 (Me); 22.7, 25.4, 26.2, 28.0, 29.4, 29.5, 31.9, 32.8 (CH_2 , $\text{C}(2')$, $\text{C}(3')$, $\text{C}(4')$, $\text{C}(5')$); 33.7 ($\text{C}(6')$); 69.5, 69.7, 69.76, 69.80 (CH_2O , $\text{C}(1')$); 107.3, 107.4 ($\text{C}(1'')$, $\text{C}(4'')$, $\text{C}(5'')$, $\text{C}(8'')$, $\text{C}(9'')$, $\text{C}(12'')$); 123.6, 123.68, 123.70, 123.8 ($\text{C}(4''\text{a})$, $\text{C}(4''\text{b})$, $\text{C}(8''\text{a})$, $\text{C}(8''\text{b})$, $\text{C}(12''\text{a})$, $\text{C}(12''\text{b})$); 148.9,

149.01, 149.04, 149.1 (C(2''), C(3''), C(6''), C(7''), C(10''), C(11'')). APCI-MS: 1049.7 ($[M+H]^+$), 937.6 ($[M+H-C_8H_{18}]^+$), 885.7 ($[M+H-BrC_6H_{13}]^+$), 825.4, 773.6, 713.3, 661.4, 601.2, 549.3, 531.3, 489.1, 437.2, 325.1. HR-APCI-MS: 1047.7023 and 1049.7017 ($[M+H]^+$, $C_{63}H_{103}BrO_6^+$; calc. 1047.7077 and 1049.7009).

10.3. 2-[(6-Bromohexyl)oxy]-3,6,7,10,11-pentakis(dodecyloxy)triphenylene (**14c**). As described for **14a**, from 3,6,7,10,11-pentakis(dodecyloxy)triphenylene-2-ol (1.38 g, 1.19 mmol) and 1,6-dibromohexane (2.12 g, 8.93 mmol): 1.38 g (87%) of **14c**. R_f 0.74 (hexanes/AcOEt 10:1). M.p. 49°. FT-IR (ATR): 3102w, 2918s, 2849s, 2546w, 2369w, 2179w, 1976w, 1617m, 1516s, 1436s, 1387s, 1259s, 1172s, 1045s, 836m. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.90 (m, 5 Me); 1.23–1.47 (m, 40 CH_2); 1.52–1.63 (m, 14 H, CH_2 , 2 H–C(3'), 2 H–C(4')); 1.89–1.98 (m, 14 H, CH_2 , 2 H–C(2'), 2 H–C(5')); 3.44 (t, $J=6.8$, 2 H–C(6')); 4.22 (t, $J=6.6$, 4 CH_2O); 4.23 (t, $J=6.4$, CH_2O); 7.83 (s, 6 arom. H). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 25.4, 26.2, 28.0, 29.3, 29.4, 29.5, 29.6, 29.70, 29.72, 29.8, 32.0, 32.8 (CH_2 , C(2'), C(3'), C(4'), C(5')); 33.7 (C(6')); 69.5, 69.6, 69.72, 69.74 (OCH_2 , C(1')); 107.2, 107.4 (C(1''), C(4''), C(5''), C(8''), C(9''), C(12'')); 123.56, 123.57, 123.63, 123.65, 123.72 (C(4'a), C(4'b), C(8'a), C(8'b), C(12'a), C(12'b)); 148.8, 148.9, 148.97, 148.99, 149.00, 149.01 (C(2''), C(3''), C(6''), C(7''), C(10''), C(11'')). APCI-MS: 1330.0 ($[M+H]^+$), 1161.8 ($[M+H-C_{12}H_{26}]^+$), 993.6, 825.4, 643.4, 475.3, 325.1. Anal. calc. for $C_{84}H_{143}BrO_6$ (1328.93): C 75.92, H 10.85, N 6.01; found: C 76.12, H 10.72, N 5.93.

11.1. [1,1'-Biisoquinoline]-4,4'-diylbis(oxyhexane-6,1-diyl) Bis[(3,4,5-tris(alkyloxy)benzoates] **13d–f**. Bis-benzoates **13d–f** were prepared as described below for **13b,g,h**. For yields and m.p.s. of **13b,d–h**, see Table.

11.2. [1,1'-Biisoquinoline]-4,4'-diylbis(oxyhexane-6,1-diyl) Bis[(3,4,5-tris(octyloxy)benzoate] (**13b**). In analogy to [19], a suspension of **4a**·2 HCl (185 mg, 275 μ mol) and anh. K_2CO_3 (230 mg, 1.66 mmol) in anh. DMF (10 ml) was stirred at 100° for 1 h. After addition of **11b** (185 mg, 275 μ mol), the mixture was stirred at 100° for another 17 h. The mixture was hydrolyzed with H_2O (10 ml) and extracted with CH_2Cl_2 (3 × 10 ml). The org. layer was washed with H_2O and brine (10 ml each), dried (Na_2SO_4), and concentrated. The residue was purified by FC (SiO_2 , hexanes/AcOEt 10:1, 5:1, and 2:1): **13b** (156 mg, 77%). R_f 0.53 (hexanes/AcOEt 2:1). FT-IR (ATR): 3066w, 2951s, 2919s, 2825s, 2366w, 2169w, 1981w, 1707s, 1588s, 1579s, 1503s, 1468s, 1455s, 1428s, 1332s, 1296s, 1247s, 1218s, 1118s, 1097s, 985s, 858m, 780s, 764s. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.90 (m, 6 Me); 1.26–1.38 (m, 24 CH_2); 1.43–1.52 (m, 6 CH_2); 1.57–1.67 (m, 4 H, 2 H–C(4')); 1.69–1.92 (m, 20 H, CH_2 , 2 H–C(3'), 2 H–C(5')); 1.97–2.08 (m, 4 H, 2 H–C(2')); 4.02 (t, $J=6.6$, 4 H, CH_2O –C(4')); 4.02 (t, $J=6.5$, 8 H, CH_2O –C(3'), CH_2O –C(5')); 4.34 (t, $J=6.3$, 4 H, 2 H–C(1')); 4.36 (t, $J=6.8$, 4 H, 2 H–C(6')); 7.28 (s, 4 H, H–C(2''), H–C(6'')); 7.47 (ddd, $J=8.5$, 6.9, 1.3, 2 H, H–C(7)); 7.68 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H–C(6)); 7.74 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H–C(8)); 8.24 (br. s, 2 H, H–C(3)); 8.33 (ddd, $J=8.5$, 1.3, 0.8, 2 H, H–C(5)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.68, 22.70, 25.9, 26.0, 26.06, 26.10, 28.8, 29.29, 29.33, 29.4, 29.5, 30.3, 31.8, 31.9 (CH_2 , C(2'), C(3'), C(4'), C(5')); 65.0 (C(6')); 68.7 (C(1')); 69.2 (CH_2O); 73.5 (CH_2O); 108.1 (C(2''), C(6'')); 121.3 (C(5)); 122.5 (C(3)); 125.0 (C(1'')); 126.9 (C(8)); 127.7 (C(7)); 128.5 (C(8a)); 129.1 (C(4a)); 129.4 (C(6)); 142.4 (C(4'')); 149.9 (C(4)); 150.4 (C(1)); 152.8 (C(3''), C(5'')); 166.5 (COO). ESI-MS: 1467.0 ($[M+H]^+$), 1353.9 ($[M-C_8H_{18}]^+$), 1253.8, 1141.7, 959.6, 877.6 ($[M+H-R]^+$), 765.4, 665.3, 489.4, 377.3, 289.1. Anal. calc. for $C_{92}H_{140}N_2O_{12}$ (1466.10): C 75.37, H 9.62, N 1.91; found: C 75.12, H 9.52, N 1.88.

11.3. [1,1'-Biisoquinoline]-4,4'-diylbis(oxyhexane-6,1-diyl) Bis[(3,4,5-tris(tetradecyloxy)benzoate] (**13g**). As described for **13b**, from **4a**·2 HCl (185 mg, 275 μ mol) and **11g** (301 mg, 304 μ mol): 163 mg (60%) of **13g**. R_f 0.53 (hexanes/AcOEt 2:1). FT-IR (ATR): 2916s, 2849s, 1712s, 1579s, 1428s, 1335s, 1300s, 1212s, 1095s, 993m, 767s, 720s. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.90 (m, 6 Me); 1.26–1.38 (m, 60 CH_2); 1.43–1.52 (m, 6 CH_2); 1.57–1.67 (m, 4 H, 2 H–C(4')); 1.69–1.92 (m, 20 H, CH_2 , 2 H–C(3'), 2 H–C(5')); 1.97–2.08 (m, 4 H, 2 H–C(2')); 4.01 (t, $J=6.6$, 2 CH_2O); 4.02 (t, $J=6.5$, 4 CH_2O); 4.34 (t, $J=6.3$, 4 H, 2 H–C(1')); 4.35 (t, $J=6.8$, 4 H, 2 H–C(6')); 7.28 (s, 4 H, H–C(2''), H–C(6'')); 7.47 (ddd, $J=8.5$, 6.9, 1.3, 2 H, H–C(7)); 7.68 (ddd, $J=8.5$, 6.9, 1.2, 2 H, H–C(6)); 7.74 (ddd, $J=8.5$, 1.2, 0.8, 2 H, H–C(8)); 8.24 (s, 2 H, H–C(3)); 8.33 (ddd, $J=8.5$, 1.3, 0.8, 2 H, H–C(5)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 25.9, 26.0, 26.1, 28.8, 29.3, 29.38, 29.43, 29.6, 29.67, 29.73, 30.4, 32.0 (CH_2 , C(2'), C(3'), C(4'), C(5')); 64.9 (C(6')); 68.8 (C(1')); 69.3 (CH_2O); 73.5 (CH_2O); 108.1 (C(2''), C(6'')); 121.4 (C(5)); 122.4 (C(3)); 125.0 (C(1'')); 126.9 (C(8)); 127.8 (C(7)); 128.5 (C(8a)); 129.2 (C(4a)); 129.5 (C(6)); 142.5 (C(4'')); 150.0 (C(4)); 150.4 (C(1)); 152.9 (C(3''), C(5'')); 166.5 (COO). APCI-MS: 1971.6 ($[M+H]^+$),

1775.4 ($[M + H - C_{14}H_{30}]^+$), 1591.2, 1394.0, 1212.9, 1129.8 ($[M + 2H - R]^+$), 933.6, 741.7, 545.5, 349.2, 289.1. Anal. calc. for $C_{128}H_{212}N_2O_{12}$ (1971.06): C 78.00, H 10.84, N 1.42; found: C 78.03, H 10.74, N 1.40.

11.4. *[1,1'-Biisoquinoline]-4,4'-diylbis(oxyhexane-6,1-diyl) Bis[(3,4,5-tris(hexadecyloxy)benzoate] (13h)*. As described for **13b**, from **4a**·2 HCl (185 mg, 275 μ mol) and **11h** (613 mg, 609 μ mol): 216 mg (36%) of **13h**. R_f 0.64 (hexanes/AcOEt 2:1). FT-IR (ATR): 2916s, 2848s, 2185w, 1973w, 1709s, 1579m, 1467s, 1429s, 1330s, 1302s, 1219s, 1116s, 1099s, 991m, 866m, 767s, 720m. 1H -NMR (300 MHz, $CDCl_3$): 0.86–0.90 (m, 6 Me); 1.26–1.38 (m, 72 CH_2); 1.43–1.52 (m, 6 CH_2); 1.57–1.67 (m, 4 H, 2 H–C(4'')); 1.69–1.92 (m, 20 H, CH_2 , 2 H–C(3'), 2 H–C(5'')); 1.97–2.08 (m, 4 H, 2 H–C(2'')); 4.02 (t, J = 6.6, 2 CH_2O –C(4'')); 4.02 (t, J = 6.5, 8 H, CH_2O –C(3''), CH_2O –C(5'')); 4.34 (t, J = 6.3, 4 H, 2 H–C(1'')); 4.36 (t, J = 6.8, 4 H, 2 H–C(6'')); 7.28 (s, 4 H, H–C(2''), H–C(6'')); 7.47 (ddd, J = 8.5, 6.9, 1.3, 2 H, H–C(7'')); 7.68 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(6'')); 7.74 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(8'')); 8.24 (s, 2 H, H–C(3'')); 8.33 (ddd, J = 8.5, 1.3, 0.8, 2 H, H–C(5'')). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 25.9, 26.0, 26.09, 26.12, 28.8, 29.2, 29.36, 29.38, 29.44, 29.6, 29.67, 29.68, 29.73, 29.8, 30.4, 31.9 (CH_2 , C(2'), C(3'), C(4'), C(5'')); 64.9 (C(6'')); 69.0 (C(1'')); 69.3 (CH_2O); 73.5 (CH_2O); 108.1 (C(2''), C(6'')); 121.6 (C(5'')); 122.4 (C(3'')); 125.0 (C(1'')); 127.0 (C(8'')); 128.2 (C(7'')); 128.4 (C(4a), C(8a)); 129.4 (C(6'')); 142.5 (C(4'')); 149.8 (C(4'')); 150.3 (C(1'')); 152.9 (C(3''), C(5'')); 166.5 (COO). APCI-MS: 2139.8 ($[M + H]^+$), 1915.5 ($[M + H - C_{16}H_{34}]^+$), 1703.3, 1237.0, 1213.9, 989.7, 825.8, 601.5, 379.3. Anal. calc. for $C_{140}H_{236}N_2O_{12}$ (2139.38): C 78.60, H 11.12, N 1.31; found: C 78.40, H 11.00, N 1.27.

11.5. *4,4'-Bis{[6-[[3-methoxy-6,7,10,11-tetrakis(octyloxy)triphenylen-2-yl]oxy]hexyl]oxy}-1,1'-biisoquinoline (15a)*. As described for **13b**, from **4a**·2 HCl (100 mg, 207 μ mol), **14a** (579 mg, 609 μ mol), and K_2CO_3 (612 mg, 4.43 mmol) with stirring for 45 h and purification by FC (SiO_2 , hexanes/AcOEt 20:1, 10:1, 5:1, 4:1, 3:1, 2:1, 1:1, and 2:3): 387 mg (69%) of **15a**. R_f 0.60 (hexanes/AcOEt 1:1). FT-IR (ATR): 3069w, 2921s, 2852s, 2367w, 2186w, 1970w, 1616m, 1507s, 1427s, 1258s, 1162s, 1042s, 835s, 767m. 1H -NMR (300 MHz, $CDCl_3$): 0.87–0.92 (m, 8 Me); 1.28–1.47 (m, 32 CH_2); 1.53–1.63 (m, 8 CH_2); 1.75–1.80 (m, 8 H, 2 H–C(3'), 2 H–C(4'')); 1.90–1.99 (m, 8 CH_2); 2.04–2.13 (m, 8 H, 2 H–C(2''), 2 H–C(5'')); 4.10 (s, 2 MeO); 4.23 (t, J = 6.6, 4 H, CH_2O –C(6'')); 4.24 (t, J = 6.6, 12 H, CH_2O –C(7''), CH_2O –C(10''), CH_2O –C(11'')); 4.32 (t, J = 6.4, 4 H, 2 H–C(6'')); 4.37 (t, J = 6.3, 4 H, 2 H–C(1'')); 7.46 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(7'')); 7.66 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(6'')); 7.73 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(8'')); 7.81–7.86 (m, 12 H, H–C(1''), H–C(4''), H–C(5''), H–C(8''), H–C(9''), H–C(12'')); 8.26 (s, 2 H, H–C(3'')); 8.34 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(5'')). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 26.08, 26.13, 26.2, 29.4, 29.5, 31.9 (CH_2 , C(2'), C(3'), C(4'), C(5'')); 56.3 (MeO); 68.7 (C(1'')); 69.2 (C(6'')); 69.7, 69.8 (CH_2O); 105.0, 106.4, 107.3, 107.5 (C(1''), C(4''), C(5''), C(8''), C(9''), C(12'')); 121.4 (C(5'')); 122.4 (C(3'')); 123.4, 123.46, 123.54, 123.65, 123.68 (C(4'a), C(4'b), C(8'a), C(8'b), C(12'a), C(12'b)); 126.9 (C(8'')); 127.8 (C(7'')); 128.5 (C(8a)); 129.1 (C(4a)); 129.5 (C(6'')); 148.4, 148.99, 149.01, 149.03, 149.1, 149.2 (C(2''), C(3''), C(6''), C(7''), C(10''), C(11'')); 150.1 (C(4'')); 150.4 (C(1')). APCI-MS: 2027.4 ($[M + H]^+$), 1902.2, 1838.2, 1201.8, 1014.7. Anal. calc. for $C_{132}H_{188}N_2O_{14}$ (2026.91): C 78.22, H 9.35, N 1.38; found: C 78.27, H 9.30, N 1.37.

11.6. *4,4'-Bis{[6-[[3,6,7,10,11-pentakis(octyloxy)triphenylen-2-yl]oxy]hexyl]oxy}-1,1'-biisoquinoline (15b)*. As described for **13b**, from **4a**·2 HCl (100 mg, 207 μ mol), **14b** (639 mg, 609 μ mol), and K_2CO_3 (612 mg, 4.43 mmol) with stirring for 45 h and purification by FC (SiO_2 , hexanes/AcOEt 20:1, 10:1, 5:1, and 4:1): 193 mg (31%) of **15b**. R_f 0.47 (hexanes/AcOEt 4:1). FT-IR (ATR): 2882s, 1682m, 1558s, 1485s, 1407s, 1350s, 1188m, 1086s, 929s, 743s, 679s. 1H -NMR (300 MHz, $CDCl_3$): 0.85–0.92 (m, 10 Me); 1.27–1.47 (m, 40 CH_2); 1.53–1.63 (m, 10 CH_2); 1.75–1.80 (m, 8 H, 2 H–C(3'), 2 H–C(4'')); 1.90–1.99 (m, 10 CH_2); 2.03–2.11 (m, 8 H, 2 H–C(2''), 2 H–C(5'')); 4.23 (t, J = 6.6, 16 H, CH_2O –C(6''), CH_2O –C(7''), CH_2O –C(10''), CH_2O –C(11'')); 4.24 (t, J = 6.5, 4 H, CH_2O –C(3'')); 4.30 (t, J = 6.4, 4 H, 2 H–C(6'')); 4.37 (t, J = 6.3, 4 H, 2 H–C(1'')); 7.46 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(7'')); 7.65 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(6'')); 7.74 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(8'')); 7.83–7.87 (m, 12 H, H–C(1''), H–C(4''), H–C(5''), H–C(8''), H–C(9''), H–C(12'')); 8.25 (s, 2 H, H–C(3'')); 8.34 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(5'')). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 26.1, 26.2, 29.4, 29.5, 31.9 (CH_2 , C(2'), C(3'), C(4'), C(5'')); 68.8 (C(1'')); 69.6 (C(6'')); 69.6, 69.7, 69.8 (OCH_2); 107.2, 107.3, 107.35, 107.42 (C(1''), C(4''), C(5''), C(8''), C(9''), C(12'')); 121.4 (C(5'')); 122.4 (C(3'')); 123.60, 123.64, 123.7 (C(4'a), C(4'b), C(8'a), C(8'b), C(12'a), C(12'b)); 126.9 (C(8'')); 127.8 (C(7'')); 128.5 (C(8a)); 129.1 (C(4a)); 129.5 (C(6'')); 148.9, 149.0 (C(2''), C(3''), C(6''), C(7''), C(10''), C(11'')); 150.0 (C(4'')); 150.4 (C(1')). APCI-MS: 2223.6 ($[M + H]^+$),

1971.5, 1338.9, 1299.9, 1186.9, 1160.9, 1112.8, 1070.8, 1026.8, 985.8, 967.8, 873.7, 855.7. Anal. calc. for $C_{146}H_{216}N_2O_{14}$ (2223.28): C 78.87, H 9.79, N 1.26; found: C 78.73, H 9.65, N 1.22.

11.7. 4,4'-Bis[6-[[3,6,7,10,11-pentakis(dodecyloxy)triphenylen-2-yl]oxy]hexyl]oxy-1,1'-biisoquinoline (**15c**). As described for **13b**, from **4a** · 2 HCl (100 mg, 207 μ mol), **14c** (809 mg, 609 μ mol), and K_2CO_3 (612 mg, 4.43 mmol) with stirring for 45 h and purification by FC (SiO_2 , hexanes/AcOEt 20:1, 10:1, 8:1, 5:1, and 2:1): 105 mg (14%) of **15c**. R_f 0.56 (hexanes/AcOEt 4:1). FT-IR (ATR): 3077w, 2918s, 2849s, 2559w, 2368w, 2119w, 1969w, 1617m, 1517s, 1436s, 1387s, 1259s, 1172s, 1044m, 836s, 721m. 1H -NMR (300 MHz, $CDCl_3$): 0.83–0.90 (m, 10 Me); 1.22–1.47 (m, 80 CH_2); 1.52–1.62 (m, 10 CH_2); 1.75–1.80 (m, 8 H, 2 H–C(3'), 2 H–C(4')); 1.90–1.99 (m, 10 CH_2); 2.03–2.13 (m, 8 H, 2 H–C(2'), 2 H–C(5')); 4.23 (t, J = 6.6, 16 H, CH_2O –C(6''), CH_2O –C(7''), CH_2O –C(10''), CH_2O –C(11'')); 4.24 (t, J = 6.5, 4 H, CH_2O –C(3'')); 4.30 (t, J = 6.4, 4 H, 2 H–C(6'')); 4.37 (t, J = 6.3, 4 H, 2 H–C(1'')); 7.46 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(6) or H–C(7)); 7.65 (ddd, J = 8.5, 6.9, 1.2, 2 H, H–C(6) or H–C(7)); 7.74 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(5) or H–C(8)); 7.83–7.87 (m, 12 H, H–C(1''), H–C(4''), H–C(5''), H–C(8''), H–C(9''), H–C(12'')); 8.25 (s, 2 H, H–C(3)); 8.34 (ddd, J = 8.5, 1.2, 0.8, 2 H, H–C(5) or H–C(8)). ^{13}C -NMR (75 MHz, $CDCl_3$): 14.1 (Me); 22.7, 26.16, 26.23, 29.4, 29.5, 29.6, 29.70, 29.73, 29.8, 31.9 (CH_2 , C(2'), C(3'), C(4'), C(5')); 68.8 (C(1'')); 69.6 (C(6'')); 69.7 (CH_2O); 107.2, 107.4 (C(1''), C(4''), C(5''), C(8''), C(9''), C(12'')); 121.4 (C(5)); 122.4 (C(3)); 123.6, 123.7 (C(4'a), C(4'b), C(8'a), C(8'b), C(12'a), C(12'b)); 126.9 (C(8)); 127.8 (C(7)); 128.5 (C(8a)); 129.1 (C(4a)); 129.5 (C(6)); 148.9, 149.0 (C(2''), C(3''), C(6''), C(7''), C(10''), C(11'')); 150.0 (C(4)); 150.4 (C(1)). APCI-MS: 2785.3 ($[M+H]^+$), 2658.0, 2596.1, 2475.9, 2223.6, 2122.0, 1992.5, 1648.2. HR-APCI-MS: 2785.2624 ($[M+H]^+$, $C_{186}H_{296}N_2O_{14}$; calc. 2785.2652).

REFERENCES

- [1] B.-H. Ye, M.-L. Tong, X.-M. Chen, *Coord. Chem. Rev.* **2005**, *249*, 545; A. P. Smith, C. L. Fraser, in 'Comprehensive Coordination Chemistry II', Eds. J. A. McCleverty and T. J. Meyer, Elsevier, Oxford, 2004, Vol. 1, p. 1; A. V. Malkov, P. Kocovsky, *Curr. Org. Chem.* **2003**, *7*, 1737; N. C. Fletcher, *J. Chem. Soc., Perkin Trans. 1* **2002**, 1831; R. Ziesel, *Coord. Chem. Rev.* **2001**, *216*, 195; C. Kaes, A. Katz, M. W. Hosseini, *Chem. Rev.* **2000**, *100*, 3553.
- [2] L. Mei, L. X. Xuan, *Asian J. Chem.* **2006**, *18*, 2089; K. Ding, X. Li, B. Ji, H. Guo, M. Kitamura, *Curr. Org. Synth.* **2005**, *2*, 499; J. M. Brunel, *Chem. Rev.* **2005**, *105*, 857; C.-M. Che, J.-S. Huang, *Coord. Chem. Rev.* **2003**, *242*, 97; S. G. Telfer, R. Kuroda, *Coord. Chem. Rev.* **2002**, *242*, 33; T. T.-L. Au-Yeung, S.-S. Chan, A. S. C. Chan, *Adv. Synth. Catal.* **2003**, *345*, 537; T. Wabnitz, O. Reiser, in 'Organic Synthesis Highlights IV', Ed. H. G. Schmalz, Wiley-VCH, Weinheim, 2000, p. 155; S. Akutagawa, *Appl. Catal., A* **1995**, *128*, 171.
- [3] R. Hrdina, I. Valterová, J. Hodačová, I. Cisarová, M. Kotora, *Adv. Synth. Catal.* **2007**, *349*, 822; R. Hrdina, A. Kadlakova, I. Valterova, J. Hodacova, M. Kotora, *Tetrahedron: Asymmetry* **2006**, *17*, 3185.
- [4] N. Boudet, J. R. Lachs, P. Knochel, *Org. Lett.* **2007**, *9*, 5525.
- [5] J. Hashim, C. O. Kappe, *Adv. Synth. Catal.* **2007**, *349*, 2353.
- [6] P. R. Blakemore, S. D. Milicevic, L. N. Zakharov, *J. Org. Chem.* **2007**, *72*, 9368.
- [7] E. Kapatsina, M. Lordon, A. Baro, S. Laschat, *Synthesis* **2008**, 2551.
- [8] S. Laschat, A. Baro, N. Steinke, F. Giesselmann, C. Hägele, G. Scalia, R. Judele, E. Kapatsina, S. Sauer, A. Schreivogel, M. Tosoni, *Angew. Chem.* **2007**, *119*, 4916; *Angew. Chem., Int. Ed.* **2007**, *46*, 4832; D. Demus, J. Goodby, G. W. Gray, H.-W. Spiess, V. Vill, 'Handbook of Liquid Crystals', Vol. 1–3, Wiley-VCH, Weinheim, 1998.
- [9] a) Y. Fukuda, S. Seto, H. Furuta, H. Ebisu, Y. Oomori, S. Terashima, *J. Med. Chem.* **2001**, *44*, 1396; b) S. Punna, S. Meunier, M. G. Finn, *Org. Lett.* **2004**, *6*, 2777.
- [10] C. Bolm, M. Ewald, M. Zehnder, M. A. Neuburger, *Chem. Ber.* **1992**, *125*, 453.
- [11] C. Naumann, H. Langhals, *Synthesis* **1990**, 279.
- [12] O. Mongin, P. Rocca, L. Thomas-dit-Dumont, F. Trécourt, F. Marsais, A. Godard, G. Quéguiner, *J. Chem. Soc., Perkin Trans. 1* **1995**, 2503; H.-A. Hasseberg, H. Gerlach, *Liebigs Ann. Chem.* **1989**, 255.

- [13] a) R. J. Kazlauskas, *J. Am. Chem. Soc.* **1989**, *111*, 4953; b) M. Süsse, S. Johné, M. Hesse, *Helv. Chim. Acta* **1992**, *75*, 457.
- [14] K. Fujii, S. Nakano, E. Fujita, *Synthesis* **1975**, 276.
- [15] J. S. Amato, S. Karady, M. Sletzing, L. M. Weinstock, *Synthesis* **1979**, 970.
- [16] J. P. Yardley, H. Fletcher, *Synthesis* **1976**, 244.
- [17] www.ccdc.ac.uk/data_request/cif.
- [18] G. S. Lim, B. M. Jung, S. Y. Lee, H. H. Song, C. Kim, J. Y. Chang, *Chem. Mater.* **2007**, *19*, 460.
- [19] R. Andreu, J. Garín, J. Orduna, J. Barberá, J. L. Serrano, T. Sierra, M. Sallé, A. Gorgues, *Tetrahedron* **1998**, *54*, 3895.
- [20] a) S. Kumar, B. Lakshmi, *Tetrahedron Lett.* **2005**, *46*, 2603; b) J. L. Schulte, S. Laschat, V. Vill, E. Nishikawa, H. Finkelmann, M. Nimtz, *Eur. J. Org. Chem.* **1998**, 2499; c) N. Boden, R. C. Borner, R. J. Bushby, A. N. Cammidge, M. V. Jesudason, *Liq. Cryst.* **1993**, *15*, 851.
- [21] S. Kumar, J. J. Naidu, S. K. Varshney, *Mol. Cryst. Liq. Cryst.* **2004**, *411*, 355.
- [22] G. Cooke, F. Hell, S. Violini, *Synth. Commun.* **1997**, *27*, 3745; O. V. Zemtsova, K. N. Zheleznov, *Russ. Chem. Bull.* **2004**, *53*, 1743; H. Monobe, Y. Shimizu, S. Okamoto, H. Enomoto, *Mol. Cryst. Liq. Cryst.* **2007**, *476*, 31.

Received March 12, 2009